MESA LABORATORIES INC /CO/ Annual Report - How They Did This Year

I’ve put together this guide to help you understand Mesa Laboratories’ performance over the past year. Think of this as a "cheat sheet" to help you decide if this company fits your investment goals.

1. What does this company do?

Mesa Laboratories provides the "safety checks" other companies need to ensure their products meet government rules. They operate in four key areas:

• Sterilization and Disinfection Control: Testing medical equipment to ensure it is sterile.
• Biopharmaceutical Development: Providing tools for protein analysis and drug research.
• Calibration Solutions: Making precision tools to measure gas flow, temperature, and pressure.
• Clinical Genomics: Offering specialized testing services for genetic research.

Their business model mixes hardware sales with recurring sales of testing kits. These kits are vital because they create steady income—much like how a printer company makes money on ink long after selling you the printer. For the fiscal year ending March 31, 2026, Mesa generated $208.4 million in total revenue, largely driven by these recurring sales.

2. Financial performance: The "Big Numbers"

Mesa continued its "buy-and-build" strategy throughout the 2026 fiscal year.

• Revenue Growth: Total revenue grew 3.4% compared to last year.
  • Calibration Solutions (their largest segment) grew 3.5%, boosted by price increases and strong service contracts.
  • Clinical Genomics revenue fell 3.6%. However, if you exclude sales to China, the rest of that division grew by 9.2%.
  • Biopharmaceutical Development remained flat, as growth in peptide products was offset by a decline in immunoassay sales.
• Profitability: The company’s gross profit margin improved to 62.4%. In Clinical Genomics, they improved margins by 2.8 percentage points by focusing on high-margin kits and cutting manufacturing costs.
• Efficiency: Mesa is managing costs better. Selling expenses dropped 2.1% this year due to reduced spending on commissions and training.

3. Major wins and challenges

• The "Mesa Way": The company uses a lean-management system to cut waste and improve performance.
• Leadership Transition: Dr. Siddhartha Kadia becomes CEO in fiscal year 2027. The company invested $4.2 million in severance and transition costs this year to prepare for this shift.
• Global Exposure: About 53% of revenue comes from outside the U.S. This provides growth but makes the company sensitive to currency swings and international trade rules.
• Operational Costs: General and administrative expenses rose 7.3% to $58.9 million, reflecting the costs associated with the leadership transition.

4. Financial health and operational risks

• Debt: Mesa carries $145 million in long-term debt. If credit markets tighten, higher interest costs could impact growth.
• Stock Dilution: Mesa may issue more shares to fund acquisitions or pay employees, which can reduce your ownership percentage.
• Dialysis Risk: The "Dialyguard" line makes up 30% of the Calibration division's revenue. If the industry shifts to new machines that do not require these specific tools, that revenue stream could be affected.
• Intangible Assets: They hold $270.2 million in "goodwill and intangible assets." If past acquisitions underperform, the company may have to write down their value, which would impact total profit.
• Cybersecurity: New digital security standards, such as the EU’s "Cyber Resilience Act," may increase future compliance costs.

5. Future outlook

Management is focused on steady, incremental growth. They plan to continue their "buy-and-build" strategy, using acquisitions to enter new markets. They are also seeking U.S. regulatory clearance for certain GKE products to open new revenue streams. The company ended the year with $22.1 million in cash to support these goals.

Investor Takeaway: Mesa Laboratories is a company built on recurring revenue and lean operations. When considering an investment, weigh their ability to successfully integrate new acquisitions and manage the upcoming CEO transition against the risks of their debt load and reliance on international markets.